GleamWall
中文EN

INAB IN8BIO, INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1740279 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY6.1%
TTM EPS YoY80.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-141.8%
ROA-109.4%
ROIC (approx.)-1,362.1%
Asset turnover—

Leverage & solvency

Liabilities / assets24.2%
Debt / equity0.00x
Current ratio5.78x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.76x
Accruals ratio-26.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$2.60M$2.49M$2.61M$2.65M$2.10M$2.49M$2.97M$3.59M
SG&A expense$2.12M$2.44M$2.65M$2.38M$1.86M$2.71M$2.69M$2.63M
Operating income-$4.59M-$4.78M-$5.09M-$4.94M-$3.85M-$5.09M-$5.55M-$6.16M
Net income-$4.59M-$4.78M-$5.09M-$4.94M-$3.85M-$5.09M-$5.55M-$6.16M
EBITDA-$4.09M-$4.48M-$4.84M-$4.70M-$3.65M-$4.79M-$5.29M-$5.91M
EPS (basic)-0.24-0.25-0.26—-0.85-1.24-2.16—
EPS (diluted)-0.24-0.25-0.26—-0.85-1.24-2.16—
Weighted avg. shares (diluted)19.47M19.47M19.47M—4.54M4.12M2.58M—
Balance sheet
Cash & equivalents$14.15M$18.13M$22.16M$27.31M$10.96M$13.50M$12.16M$11.39M
Current assets$15.19M$18.50M$22.66M$27.88M$11.77M$13.74M$12.72M$12.58M
PP&E, net$1.34M$1.60M$1.62M$1.86M$2.10M$2.35M$2.60M$2.86M
Total assets$18.70M$21.75M$26.27M$32.28M$16.77M$19.37M$19.87M$20.94M
Current liabilities$2.63M$2.25M$2.16M$3.16M$1.70M$1.95M$2.96M$3.08M
Total liabilities$4.52M$3.38M$3.48M$4.72M$3.58M$4.13M$5.99M$6.47M
Shareholders' equity$14.17M$18.36M$22.78M$27.56M$13.19M$15.24M$13.88M$14.48M
Shares outstanding9.86M9.85M9.85M9.77M4.59M4.08M81.26M2.42M
Cash flow statement
Operating cash flow-$3.93M-$3.75M-$4.95M-$2.14M-$3.52M-$3.93M-$3.12M-$4.03M
Capital expenditure————$0$0$0—
Free cash flow————-$3.52M-$3.93M-$3.12M—
Investing cash flow$1,000-$233,000-$9,000$0$0$0$0-$33,000
Financing cash flow-$56,000-$51,000-$195,000$18.49M$989,000$5.27M$3.89M$11.19M
Depreciation & amortization$500,000$300,000$245,000$245,000$200,000$300,000$256,000$251,000
Stock-based compensation$397,000$352,000$401,000$711,000$692,000$955,000$831,000$825,000

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.